Biohit Oyj (BIOBV) Fair Value & Analysis
Healthcare · FI · Market cap €40.8M
Fair value as of: Jul 11, 2026
From 17 valuation models · updated 30 days ago
A solid business, screening 29% undervalued on our models.
What matters now
- Solid quality (51/100) at a price below fair value, the discount is the argument here, not the business quality.
- A fairly wide model range (€2.42 to €4.39) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 11, 2026.
How to read this chart
60‑month range €1.09 – €3.96 · fair‑value band €2.42 – €4.39 · the €2.68 price screens below the €3.45 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 11, 2026.
Analysis
Biohit Oyj (BIOBV) currently trades at €2.68, while our model-based Fair Value estimate is €3.45, implying the stock looks roughly 28.7% undervalued today. The Quality Score stands at 51/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Biohit Oyj generated revenue of €15.7M at a net margin of 17.4%. Revenue grew 21.1% year over year. It earns a return on equity of 20.2%. The balance sheet holds a net cash position of €1.9M. Fundamentals as of Jul 11, 2026
Our scenario range runs from €2.42 (bear case) to €4.39 (bull case); at €2.68, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 29% below its 52-week high and 22% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at 29%, BIOBV screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 17 models by family
Widest divergence: Dividend Discount (€6.89) versus Asset-Based (€0.6600). Highest evidence: Residual Income (76).
Notify me when BIOBV reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 11, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 50 · Market factors (momentum, volatility) 39
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Biohit Oyj, a biotechnology company, manufactures and sells bind acetaldehyde, diagnostic products, and systems for diagnostic analysis for the use of research institutions, healthcare, and industry worldwide.
Full company description
Biohit Oyj, a biotechnology company, manufactures and sells bind acetaldehyde, diagnostic products, and systems for diagnostic analysis for the use of research institutions, healthcare, and industry worldwide. The company offers GastroPanel quick test NT, a rapid and quantitative immunochromatographic test for the detection of Helicobacter pylori and atrophic gastritis; GastroPanel test, a blood test for diagnosis of the function and structure of stomach mucosa; GastroSoft, a software application designed to assist clinicians and general practitioners in interpreting GastroPanel test results; and GP Reader NT for the quantitative determination of various analytes in human samples. It also provides BIOHIT active B12 (HoloTC) test, BIOHIT total 25OH vitamin D test, and BIOHIT Calprotectin; BIOHIT ColonView quick test for detection of fecal occult blood (FOB) in stool samples; BIOHIT Celiac quick test, a qualitative in vitro immunochromatographic test aiding in diagnosis of celiac disease; BIOHIT H. pylori UFT300 and H.pylori tests for the diagnosis of H,pylori infection; lactose intolerance quick test kit; and Gluten Immunogenic Peptides test. In addition, it offers Acetium acetaldehyde binding products, such as the Acetium lozenge to help quit smoking and Acetium capsule for the protection of the stomach. Further, the company provides monoclonal antibodies for use in the areas of cellular pathology, neurobiology, oncology, and human gastric biomarkers research. Additionally, it offers BIOHIT FAEX sample system for the collection and handling of stool samples. The company was incorporated in 1988 and is headquartered in Helsinki, Finland.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Biohit Oyj reported revenue of €15.7M in FY2025 versus €9.4M in FY2021, a compound +13.8%/yr. Reported net income was €2.7M in FY2025.
Watch BIOBV: get an alert when its fair value changes →
Peer Group
Medical Devices · 352 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 11, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
| Getinge AB GETIB | kr 206.80 | kr 192.14 | -7% |
Compare Biohit Oyj with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Biohit Oyj (BIOBV) overvalued or undervalued?
What is the fair value of BIOBV?
What is the quality score of BIOBV?
What is the revenue of Biohit Oyj (BIOBV)?
What is the net profit margin of BIOBV?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Biohit Oyj and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.